Loading
Intrasense Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 08 Dec 2021.
Intrasense: what insiders have been doing
Every trade that managers of Intrasense disclose to AMF is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Intrasense. The previous disclosure was published on 8 June 2023.
Our records for Intrasense go back to 2021, with 1 purchase and 1 sale on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from AMF. Past trades are no guide to future returns.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€5,046
1 ops. · all time
Sell Volume
€4,840
1 ops. · all time
Since the insiders bought
- -47.3%Entry €0.61 · Close at T+365 €0.32
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
€0.24
Analyst consensus
Income statement
Revenue€3.0M
Gross profit€2.6M87% margin
EBITDA-€9.2M-308% margin
Net income-€10.8M-244.8% margin
Valuation
Beta0.57
Balance sheet & cash
Market cap€12.7M
Total debt€9.3M
Free Cash Flow-€5.9M
Profitability & ownership
ROE-314.4%
ROA-44.3%
% insiders55.4%
% institutions0.0%
Last declaration on 8 June 2023
Declarations3 total
11,000 shares@ €0.44100.0% of flowActionEuronext ParisISIN FR00111798862023DD914094
4,699 shares@ €0.4429.1% of flowActionEuronext Growth ParisISIN FR00111798862023DD913463
4,700 shares@ €1.073670.9% of flowActionEuronext Growth ParisISIN FR00111798862021DD739576
Canonical exit: 28 Jun 2021 (T+90)
3 of 3 declarations
About Intrasense
Intrasense is a French medtech company focused on medical imaging software. Founded in 2004 and headquartered in Montpellier, the company designs, develops and markets software solutions for image visualization, post-processing and clinical decision support. Its tools are primarily intended for radiologists, oncologists, surgeons and healthcare institutions. Over time, Intrasense has evolved from a radiology-oriented specialist into a broader clinical imaging platform player, with a particular emphasis on oncology, where it seeks to support diagnosis, treatment planning and patient follow-up.
The company’s flagship product is Myrian®, an advanced radiology visualization and multimodal image-processing platform designed to simplify and enhance routine image interpretation. Intrasense has also expanded its portfolio with artificial intelligence-based solutions, including DUOnco™ and Liflow®, which are aimed at oncology applications and longitudinal monitoring of cancer patients. Recent corporate communications indicate that several solutions were certified in 2024, strengthening the regulatory status of the product range and supporting the company’s move toward higher-value clinical offerings. Intrasense is also working toward a more recurring revenue model, with some solutions being commercialized under multi-year subscription arrangements.
Read moreShow less
Intrasense’s market positioning is built on clinical expertise, product innovation and a strong focus on workflow integration for radiologists. The company states that it has 20 years of experience in medical imaging and serves customers internationally, while remaining strongly anchored in France. Its headquarters are located in Montpellier, and its business has been strengthened by industrial partnership. Since June 2023, Guerbet, the French pharmaceutical group active in more than 80 countries, has been the reference shareholder, making Intrasense a subsidiary and reinforcing a strategic alliance centered on AI for medical imaging and oncology.
From a financial and strategic standpoint, Intrasense reported 2024 revenue of €2.246 million and presented a roadmap built on four pillars: innovation, product expansion, geographic expansion and financial discipline. Management has set out ambitions for double-digit activity growth in 2025 and break-even by 2027, underscoring the company’s transformation phase. Overall, Intrasense remains a niche specialist at the intersection of medical imaging software, digital health and AI, with a value proposition centered on improving diagnostic accuracy, clinical workflow efficiency and patient care.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
